- Report
- May 2024
- 50 Pages
Global
From €2548EUR$2,650USD£2,186GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- April 2023
- 95 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- January 2023
- 110 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- August 2022
- 117 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Report
- March 2019
- 746 Pages
Global
€21154EUR$22,000USD£18,147GBP
- Report
- January 2019
- 58 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Report
- January 2019
- 29 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Report
- January 2019
- 40 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Report
- January 2019
- 18 Pages
Global
From €9615EUR$10,000USD£8,249GBP
- Report
- July 2020
- 1740 Pages
Global
From €4615EUR$4,800USD£3,959GBP
- Report
- January 2021
- 143 Pages
China, Global
From €3000EUR$3,342USD£2,664GBP
Bendamustine is a chemotherapy drug used to treat certain types of leukemia. It is a bifunctional alkylating agent, meaning it has two chemical groups that can attach to DNA and interfere with its replication. It is used to treat chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphoma (NHL). Bendamustine is usually given in combination with other drugs, such as rituximab, and is often used in patients who have not responded to other treatments. It is generally well tolerated, with the most common side effects being nausea, vomiting, and fatigue.
The Bendamustine market is a competitive one, with several companies offering the drug. These include Cephalon, Teva Pharmaceuticals, and GlaxoSmithKline. Other companies, such as Merck, Bristol-Myers Squibb, and Pfizer, also offer Bendamustine in combination with other drugs. Show Less Read more
